Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment

Susan B. Bressler, Allison R. Ayala, Neil M. Bressler, Michele Melia, Haijing Qin, Frederick L. Ferris, Christina Flaxel, Scott M. Friedman, Adam R. Glassman, Lee M. Jampol, Michael E. Rauser

Research output: Contribution to journalArticle

48 Scopus citations

Abstract

IMPORTANCE: The prevalence of persistent diabetic macular edema (DME) after months of anti-vascular endothelial growth factor therapy and its effect on visual acuity are unknown. OBJECTIVE: To assess subsequent outcomes of eyes with DME persisting for 24 weeks after initiating treatment with 0.5 mg of ranibizumab. DESIGN, SETTING, AND PARTICIPANTS: We performed post hoc, exploratory analyses of a randomized clinical trial from March 20, 2007, through January 29, 2014, from 117 of 296 eyes (39.5%) randomly assigned to receive ranibizumab with persistent DME (central subfield thickness ≥250 μm on time domain optical coherence tomography) through the 24-week visit. INTERVENTIONS: Four monthly intravitreous injections of ranibizumab and then as needed per protocol. MAIN OUTCOMES AND MEASURES: Cumulative 3-year probabilities of chronic persistent DME (failure to achieve a central subfield thickness

Original languageEnglish (US)
Pages (from-to)278-285
Number of pages8
JournalJAMA Ophthalmology
Volume134
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bressler, S. B., Ayala, A. R., Bressler, N. M., Melia, M., Qin, H., Ferris, F. L., ... Rauser, M. E. (2016). Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmology, 134(3), 278-285. https://doi.org/10.1001/jamaophthalmol.2015.5346